NCT05722795View on ClinicalTrials.gov

Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 28, 2029

Study Completion Date

December 28, 2029

Conditions
Breast CancerTriple Negative Breast Cancer
Interventions
DRUG

Imatinib 400 MG Oral Tablet

One tablet daily 10 days before surgery.

Trial Locations (1)

41345

RECRUITING

Barbro Linderholm, Gothenburg

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Lund University

OTHER

lead

Vastra Gotaland Region

OTHER_GOV